Literature DB >> 24259680

Inhibition of excitatory synaptic transmission in hippocampal neurons by levetiracetam involves Zn²⁺-dependent GABA type A receptor-mediated presynaptic modulation.

Masahito Wakita1, Naoki Kotani, Kyuya Kogure, Norio Akaike.   

Abstract

Levetiracetam (LEV) is an antiepileptic drug with a unique but as yet not fully resolved mechanism of action. Therefore, by use of a simplified rat-isolated nerve-bouton preparation, we have investigated how LEV modulates glutamatergic transmission from mossy fiber terminals to hippocampal CA3 neurons. Action potential-evoked excitatory postsynaptic currents (eEPSCs) were recorded using a conventional whole-cell patch-clamp recording configuration in voltage-clamp mode. The antiepileptic drug phenytoin decreased glutamatergic eEPSCs in a concentration-dependent fashion by inhibiting voltage-dependent Na⁺ and Ca²⁺ channel currents. In contrast, LEV had no effect on eEPSCs or voltage-dependent Na⁺ or Ca²⁺ channel currents. Activation of presynaptic GABA type A (GABA(A)) receptors by muscimol induced presynaptic inhibition of eEPSCs, resulting from depolarization block. Low concentrations of Zn²⁺, which had no effect on eEPSCs, voltage-dependent Na⁺ or Ca²⁺ channel currents, or glutamate receptor-mediated whole cell currents, reduced the muscimol-induced presynaptic inhibition. LEV applied in the continuous presence of 1 µM muscimol and 1 µM Zn²⁺ reversed this Zn²⁺ modulation on eEPSCs. The antagonizing effect of LEV on Zn²⁺-induced presynaptic GABA(A) receptor inhibition was also observed with the Zn²⁺ chelators Ca-EDTA and RhodZin-3. Our results clearly show that LEV removes the Zn²⁺-induced suppression of GABA(A)-mediated presynaptic inhibition, resulting in a presynaptic decrease in glutamate-mediated excitatory transmission. Our results provide a novel mechanism by which LEV may inhibit neuronal activity.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24259680     DOI: 10.1124/jpet.113.208751

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  12 in total

Review 1.  Neuroprotection as a Potential Therapeutic Perspective in Neurodegenerative Diseases: Focus on Antiepileptic Drugs.

Authors:  D Caccamo; L R Pisani; P Mazzocchetti; R Ientile; P Calabresi; F Pisani; C Costa
Journal:  Neurochem Res       Date:  2015-12-31       Impact factor: 3.996

2.  Combined administration of levetiracetam and valproic acid attenuates age-related hyperactivity of CA3 place cells, reduces place field area, and increases spatial information content in aged rat hippocampus.

Authors:  Jonathan Robitsek; Marcia H Ratner; Tara Stewart; Howard Eichenbaum; David H Farb
Journal:  Hippocampus       Date:  2015-07-14       Impact factor: 3.899

Review 3.  Emerging therapies in traumatic brain injury.

Authors:  Patrick M Kochanek; Travis C Jackson; Nikki Miller Ferguson; Shaun W Carlson; Dennis W Simon; Erik C Brockman; Jing Ji; Hülya Bayır; Samuel M Poloyac; Amy K Wagner; Anthony E Kline; Philip E Empey; Robert S B Clark; Edwin K Jackson; C Edward Dixon
Journal:  Semin Neurol       Date:  2015-02-25       Impact factor: 3.420

4.  Effects of Etomidate on GABAergic and Glutamatergic Transmission in Rat Thalamocortical Slices.

Authors:  Bao Fu; Yuan Wang; Hao Yang; Tian Yu
Journal:  Neurochem Res       Date:  2016-08-26       Impact factor: 3.996

5.  Intramuscular atenolol and levetiracetam reduce mortality in a rat model of paraoxon-induced status epilepticus.

Authors:  Laxmikant S Deshpande; Robert E Blair; Matthew Halquist; Leon Kosmider; Robert J DeLorenzo
Journal:  Ann N Y Acad Sci       Date:  2020-09-22       Impact factor: 5.691

Review 6.  Mechanisms of Action of Antiseizure Drugs and the Ketogenic Diet.

Authors:  Michael A Rogawski; Wolfgang Löscher; Jong M Rho
Journal:  Cold Spring Harb Perspect Med       Date:  2016-05-02       Impact factor: 6.915

7.  Paired Burst Stimulation Causes GABAA Receptor-Dependent Spike Firing Facilitation in CA1 of Rat Hippocampal Slices.

Authors:  Takashi Tominaga; Yoko Tominaga
Journal:  Front Cell Neurosci       Date:  2016-01-29       Impact factor: 5.505

Review 8.  Hippocampal Hyperactivity as a Druggable Circuit-Level Origin of Aberrant Salience in Schizophrenia.

Authors:  Dennis Kätzel; Amy R Wolff; Alexei M Bygrave; David M Bannerman
Journal:  Front Pharmacol       Date:  2020-10-16       Impact factor: 5.810

Review 9.  Levetiracetam for neuropathic pain in adults.

Authors:  Philip J Wiffen; Sheena Derry; R Andrew Moore; Michael P T Lunn
Journal:  Cochrane Database Syst Rev       Date:  2014-07-07

Review 10.  Mechanisms of levetiracetam in the control of status epilepticus and epilepsy.

Authors:  Laxmikant S Deshpande; Robert J Delorenzo
Journal:  Front Neurol       Date:  2014-01-31       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.